AFFIRM-AHF: Ferric Carboxymaltose in Iron-Deficient Patients Discharged After Acute Heart Failure

High-dose trivalent influenza vaccine comparable to standard-dose quadrivalent vaccine in deaths or cardiopulmonary hospitalizations in high-risk CV disease; AHA results reported by CCO

Vericiguat VICTORIA subgroup analysis from AHA, as reported by CCO

Omecamtiv mecarbil reduced time to first heart failure event or cardiovascular death in patients with heart failure with reduced ejection fraction: GALACTIC-HF data from AHA 2020 as reported by CCO

CCO’s Expert insights from ACC.20/WCC: Akshay S. Desai, MD, MPH discusses recent findings from practice-changing heart failure studies

Akshay Suvas Desai, MD, MPH Released: April 17, 2020